Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 77.91

+1.5%

4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2097)	1/14/2008 1:30:32 PM
From: Jibacoa	Read Replies (2) of 3722

MRK opened with a DG today after it said that patients with high cholesterol fared no better when taking Vytorin than with a high dose of the generic form of Zocor. The stock is still down around 2.23% bigcharts.marketwatch.com The ENHANCE trial focused on a group of 720 patients with familial hypercholesterolemia. Patients were given either Vytorin or a high dose of Zocor. (Vytorin is a combination of SGP's Zetia & MRK's Zocor, which lost patent protection in 2006.) MRK & SGP have submitted an abstract on the ENHANCE trial for presentation at the ACC meeting, which will be held in March,& are still waiting notification of acceptance from the College. MRK's stock is still holding its present UT & hasn't closed its Apr13 UG bigcharts.marketwatch.com On Dec12 MRK was able to trade above its June 2003 H of $60.07 With some good news it may get to test its June 2001 at $71.76 The resistance from the Nov200 H at $91.47 & the Dec-Jan double top at $90.76 looks too far at present.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next